Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 known ✓ | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 known ✓ | P35228 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.80 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.46 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.41 |
| ▸ | GGT1 | P19440 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cysteine SCHEMBL6112869 | 1.00 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL27613026 | 0.97 | PTGS1 (0.84) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL28754263 | 0.95 | PTGS1 (0.73) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL6244297 | 0.95 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL28253736 | 0.95 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL6244287 | 0.95 | PTGS1 (0.80) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL28253746 | 0.93 | PTGS1 (0.76) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL21747580 | 0.92 | PTGS1 (0.84) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL27502015 | 0.92 | PTGS1 (0.84) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 | |
| Cysteine SCHEMBL17394843 | 0.92 | PTGS1 (0.94) | PTGS1SLC7A11SLC7A5ENPEPGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113862735-B | Coating liquid, coating electrode, and preparation method and application of coating liquid | 鲍宁 | 2023-08-08 | — | — | CN | disclosed |
| CN-113862735-A | Coating solution, coating electrode and preparation method and application thereof | 鲍宁 | 2021-12-31 | — | — | CN | disclosed |
| EP-2640728-B1 | NOVEL MONENSIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF PROTOZOAL INFECTIONS | MERIAL INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8822528-B2 | Monensin derivatives for the treatment and prevention of protozoal infections | MERIAL LIMITED (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2640728-A1 | NOVEL MONENSIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF PROTOZOAL INFECTIONS | Merial Limited (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068202-A1 | NOVEL MONENSIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF PROTOZOAL INFECTIONS | MERIAL LIMITED (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120128722-A1 | Novel Monensin Derivatives for the Treatment and Prevention of Protozoal Infections | MERIAL, INC. | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128722-A1 | Novel Monensin Derivatives for the Treatment and Prevention of Protozoal Infections | MON2, SLC26A4, ABCB11 | NOS1 4558/4885NOS2 4399/4885PTGS1 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.